CGEM Cullinan Therapeutics, Inc.
Nasdaq · SEC CIK 1789972 · EDGAR
- Bought, last 12 months
- $13.33M 3 purchases by 2 insiders
- Sold, last 12 months
- $2.51M 24 sales by 5 insiders
- Filings on record
- 211 since 2021-08-11, latest 2026-09-10 09:22
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Lynx1 Capital Management LP | 10% | $11.93M | — |
| Michaelson Jennifer | CSO | — | $1.62M |
| Nichols Weston | 10% | $1.39M | — |
| AHMED NADIM | Pres, CEO, Dir | — | $518.0K |
| Jones Jeffrey Alan | Chief Medical Off | — | $178.9K |
| SUMER JACQUELYN L | CLO | — | $136.7K |
| Fenton Mary Kay | CFO | — | $59.9K |
Transactions 200
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-05-16 | 2023-05-12 | CGEM | Trigilio Jeffrey | CFO | S - Sale | $8.78 | -347 | 86.9K | -0.4% | -$3,047 | |
| 2023-05-16 | 2023-05-12 | CGEM | Michaelson Jennifer | Chief Development Off | S - Sale | $8.78 | -193 | 90.7K | -0.2% | -$1,695 | |
| 2023-04-26 | 2023-04-25 | CGEM | AHMED NADIM | Pres, CEO, Dir | S - Sale | $10.59 | -716 | 117.3K | -0.6% | -$7,582 | |
| 2023-04-20 | 2023-04-18 | CGEM | Michaelson Jennifer | Chief Development Off | S - Sale | $10.71 | -238 | 90.9K | -0.3% | -$2,549 | |
| 2023-04-20 | 2023-04-18 | CGEM | Jones Jeffrey Alan | Chief Medical Off | S - Sale | $10.71 | -392 | 59.2K | -0.7% | -$4,198 | |
| 2023-04-20 | 2023-04-18 | CGEM | Trigilio Jeffrey | CFO | S - Sale | $10.71 | -398 | 87.3K | -0.5% | -$4,263 | |
| 2023-04-20 | 2023-04-18 | CGEM | SUMER JACQUELYN L | CLO | S - Sale | $10.71 | -290 | 46.4K | -0.6% | -$3,106 | |
| 2023-04-14 | 2023-04-12 | CGEM | Trigilio Jeffrey | CFO | S - Sale | $10.22 | -318 | 87.7K | -0.4% | -$3,250 | |
| 2023-04-14 | 2023-04-12 | CGEM | Michaelson Jennifer | Chief Development Off | S - Sale | $10.22 | -176 | 91.1K | -0.2% | -$1,799 | |
| 2023-03-27 | 2023-03-20 | CGEM | Jones Jeffrey Alan | Chief Medical Off | S - Sale | $11.32 | -390 | 59.6K | -0.7% | -$4,415 | |
| 2023-03-27 | 2023-03-20 | CGEM | Michaelson Jennifer | Chief Development Off | S - Sale | $11.32 | -238 | 91.3K | -0.3% | -$2,694 | |
| 2023-03-27 | 2023-03-23 | CGEM | AHMED NADIM | Pres, CEO, Dir | S - Sale | $10.51 | -706 | 118.0K | -0.6% | -$7,420 | |
| 2023-03-27 | 2023-03-20 | CGEM | Trigilio Jeffrey | CFO | S - Sale | $11.32 | -399 | 88.0K | -0.5% | -$4,517 | |
| 2023-03-27 | 2023-03-20 | CGEM | SUMER JACQUELYN L | CLO | S - Sale | $11.32 | -305 | 46.7K | -0.6% | -$3,453 | |
| D | 2023-02-23 | 2023-02-22 | CGEM | AHMED NADIM | Pres, CEO, Dir | A - Grant | $0.00 | +109.0K | 118.7K | +1,123% | $0 |
| D | 2023-02-21 | 2023-02-17 | CGEM | Savill Corrine | Chief Business Off | A - Grant | $0.00 | +20.5K | 170.1K | +14% | $0 |
| D | 2023-02-21 | 2023-02-17 | CGEM | Baeuerle Patrick | CSO | A - Grant | $0.00 | +38.5K | 76.0K | +103% | $0 |
| D | 2023-02-21 | 2023-02-17 | CGEM | SUMER JACQUELYN L | CLO | A - Grant | $0.00 | +47.0K | 47.0K | New | $0 |
| D | 2023-02-21 | 2023-02-17 | CGEM | Jones Jeffrey Alan | Chief Medical Off | A - Grant | $0.00 | +60.0K | 60.0K | New | $0 |
| D | 2023-02-21 | 2023-02-17 | CGEM | Michaelson Jennifer | Chief Development Off | A - Grant | $0.00 | +38.5K | 91.5K | +73% | $0 |
| D | 2023-02-21 | 2023-02-17 | CGEM | Trigilio Jeffrey | CFO | A - Grant | $0.00 | +47.0K | 88.4K | +114% | $0 |
| DM | 2023-01-19 | 2023-01-19 | CGEM | BVF II GP LLC | See Explanation of Responses | J - Other | — | -6.40M | 558.9K | -92% | — |
| 2023-01-06 | 2022-12-30 | CGEM | Trigilio Jeffrey | CFO | A - Grant | $8.97 | +201 | 41.4K | +0.5% | +$1,803 | |
| D | 2022-11-29 | 2022-11-25 | CGEM | Michaelson Jennifer | See Remarks | M - OptEx | $4.30 | +4,000 | 57.0K | +8% | +$17.2K |
| D | 2022-11-29 | 2022-11-25 | CGEM | Michaelson Jennifer | See Remarks | S - Sale+OE | $13.30 | -4,000 | 53.0K | -7% | -$53.2K |
| D | 2022-09-29 | 2022-09-27 | CGEM | Michaelson Jennifer | See Remarks | M - OptEx | $4.30 | +4,000 | 57.0K | +8% | +$17.2K |
| D | 2022-09-29 | 2022-09-27 | CGEM | Michaelson Jennifer | See Remarks | S - Sale+OE | $12.40 | -4,000 | 53.0K | -7% | -$49.6K |
| D | 2022-08-09 | 2022-08-08 | CGEM | Michaelson Jennifer | Chief Development Off | S - Sale+OE | $15.01 | -1,385 | 53.0K | -3% | -$20.8K |
| D | 2022-08-09 | 2022-08-08 | CGEM | Michaelson Jennifer | Chief Development Off | M - OptEx | $4.30 | +1,385 | 54.4K | +3% | +$5,956 |
| M | 2022-08-04 | 2022-08-02+ | CGEM | Jovan-Embiricos Morana | 10% | S - Sale | $14.26 | -49.9K | 1.28M | -4% | -$711.9K |
| D | 2022-07-26 | 2022-07-25 | CGEM | Michaelson Jennifer | Chief Development Off | M - OptEx | $4.30 | +8,000 | 61.0K | +15% | +$34.4K |
| D | 2022-07-26 | 2022-07-25 | CGEM | Michaelson Jennifer | Chief Development Off | S - Sale+OE | $14.51 | -8,000 | 53.0K | -13% | -$116.1K |
| M | 2022-07-21 | 2022-07-18+ | CGEM | Savill Corrine | Acting Chief Business Off | S - Sale | $15.18 | -20.0K | 149.6K | -12% | -$303.6K |
| M | 2022-07-12 | 2022-07-11 | CGEM | Savill Corrine | Acting Chief Business Off | S - Sale | $13.33 | -40.0K | 169.8K | -19% | -$533.3K |
| 2022-07-05 | 2022-06-30 | CGEM | Michaelson Jennifer | Chief Development Off | A - Grant | $10.90 | +1,620 | 53.0K | +3% | +$17.7K | |
| 2022-07-05 | 2022-06-30 | CGEM | AHMED NADIM | Pres, CEO, Dir | A - Grant | $10.90 | +1,620 | 9,710 | +20% | +$17.7K | |
| 2022-07-05 | 2022-06-30 | CGEM | Trigilio Jeffrey | CFO | A - Grant | $10.90 | +1,451 | 41.2K | +4% | +$15.8K | |
| D | 2022-06-28 | 2022-06-24 | CGEM | Jovan-Embiricos Morana | 10% | F - Tax | $13.39 | -45.1K | 207.8K | -18% | -$603.6K |
| DM | 2022-06-28 | 2022-06-24 | CGEM | Jovan-Embiricos Morana | 10% | M - OptEx | $4.30 | +140.4K | 252.9K | +125% | +$603.6K |
| M | 2022-06-23 | 2022-06-21+ | CGEM | F2 Bioscience I 2017 Ltd | 10% | S - Sale | $12.80 | -101.9K | 617.0K | -14% | -$1.30M |
| 2022-06-07 | 2022-06-06 | CGEM | AHMED NADIM | Pres, CEO, Dir | P - Purchase | $12.40 | +8,090 | 8,090 | New | +$100.3K | |
| M | 2022-06-03 | 2022-06-01 | CGEM | BIOTECHNOLOGY VALUE FUND L P | See Explanation of Responses | P - Purchase | $11.00 | +751.4K | 4.06M | +23% | +$8.27M |
| M | 2022-05-16 | 2022-05-12+ | CGEM | BVF INC/IL | 10% | P - Purchase | $9.07 | +1.11M | 3.60M | +45% | +$10.06M |
| M | 2022-05-16 | 2022-05-12+ | CGEM | F2 Vision SCS | 10% | S - Sale | $9.66 | -418.7K | 1.46M | -22% | -$4.05M |
| M | 2022-04-05 | 2022-04-01 | CGEM | BVF II GP LLC | See Explanation of Responses | P - Purchase | $10.75 | +276.0K | 3.06M | +10% | +$2.97M |
| D | 2022-02-15 | 2022-02-11 | CGEM | Michaelson Jennifer | Chief Development Off | A - Grant | $0.00 | +28.5K | 51.4K | +124% | $0 |
| D | 2022-02-15 | 2022-02-11 | CGEM | Trigilio Jeffrey | CFO | A - Grant | $0.00 | +37.5K | 39.8K | +1,667% | $0 |
| D | 2022-02-15 | 2022-02-11 | CGEM | Savill Corrine | Acting Chief Business Off | A - Grant | $0.00 | +16.5K | 209.6K | +9% | $0 |
| D | 2022-02-15 | 2022-02-11 | CGEM | Keane Raymond T | CLO | A - Grant | $0.00 | +22.5K | 24.1K | +1,385% | $0 |
| D | 2022-02-15 | 2022-02-11 | CGEM | Zawel Leigh | See Remarks | A - Grant | $0.00 | +32.5K | 69.8K | +87% | $0 |
| D | 2022-02-15 | 2022-02-11 | CGEM | Baeuerle Patrick | See Remarks | A - Grant | $0.00 | +37.5K | 37.5K | New | $0 |
| 2022-01-13 | 2022-01-11 | CGEM | Jovan-Embiricos Morana | 10% | J - Other | — | -1.19M | 1.72M | -41% | — | |
| DM | 2021-10-20 | 2021-10-18 | CGEM | Michaelson Jennifer | See Remarks | S - Sale+OE | $21.42 | -4,000 | 23.5K | -15% | -$85.7K |
| D | 2021-10-20 | 2021-10-18 | CGEM | Michaelson Jennifer | See Remarks | M - OptEx | $4.30 | +4,000 | 26.9K | +17% | +$17.2K |
| 2021-10-18 | 2021-10-15 | CGEM | Zawel Leigh | See Remarks | S - Sale | $25.00 | -19.6K | 37.3K | -34% | -$489.4K | |
| D | 2021-10-18 | 2021-10-15 | CGEM | Trigilio Jeffrey | CFO | S - Sale+OE | $25.00 | -8,000 | 2,250 | -78% | -$200.0K |
| D | 2021-10-18 | 2021-10-15 | CGEM | Trigilio Jeffrey | CFO | M - OptEx | $4.30 | +8,000 | 10.2K | +356% | +$34.4K |
| 2021-10-12 | 2021-10-07 | CGEM | Zawel Leigh | See Remarks | S - Sale | $25.00 | -1,079 | 56.9K | -2% | -$27.0K | |
| DM | 2021-09-21 | 2021-09-20 | CGEM | Michaelson Jennifer | See Remarks | S - Sale+OE | $24.51 | -4,000 | 23.7K | -14% | -$98.0K |
| D | 2021-09-21 | 2021-09-20 | CGEM | Michaelson Jennifer | See Remarks | M - OptEx | $4.30 | +4,000 | 26.9K | +17% | +$17.2K |
| 2021-09-21 | 2021-09-20 | CGEM | Zawel Leigh | See Remarks | S - Sale | $25.16 | -7,468 | 57.9K | -11% | -$187.9K | |
| I | 2021-09-20 | 2021-09-16 | CGEM | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.06 | -3,124 | 7.65M | -0.0% | -$90.8K |
| 2021-09-20 | 2021-09-16 | CGEM | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.06 | -432 | 244.6K | -0.2% | -$12.6K | |
| 2021-09-20 | 2021-09-16 | CGEM | BioImpact Capital LLC | 10% | S - Sale | $29.06 | -3,124 | 7.65M | -0.0% | -$90.8K | |
| MI | 2021-09-16 | 2021-09-14+ | CGEM | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.17 | -13.5K | 7.66M | -0.2% | -$394.6K |
| M | 2021-09-16 | 2021-09-14+ | CGEM | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.17 | -1,870 | 245.0K | -0.8% | -$54.5K |
| M | 2021-09-16 | 2021-09-14+ | CGEM | BioImpact Capital LLC | 10% | S - Sale | $29.17 | -13.5K | 7.66M | -0.2% | -$394.6K |
| M | 2021-09-13 | 2021-09-09+ | CGEM | BioImpact Capital LLC | 10% | S - Sale | $29.23 | -23.3K | 7.66M | -0.3% | -$679.7K |
| MI | 2021-09-13 | 2021-09-09+ | CGEM | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.23 | -23.3K | 7.67M | -0.3% | -$679.7K |
| M | 2021-09-13 | 2021-09-09+ | CGEM | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.23 | -3,215 | 247.3K | -1% | -$94.0K |
| D | 2021-09-09 | 2021-09-08 | CGEM | Baeuerle Patrick | See Remarks | M - OptEx | $4.30 | +11.0K | 11.0K | New | +$47.3K |
| D | 2021-09-09 | 2021-09-08 | CGEM | Baeuerle Patrick | See Remarks | S - Sale+OE | $28.45 | -11.0K | 0 | -100% | -$312.9K |
| D | 2021-09-09 | 2021-09-08 | CGEM | Trigilio Jeffrey | CFO | M - OptEx | $4.30 | +15.0K | 17.2K | +667% | +$64.5K |
| DM | 2021-09-09 | 2021-09-08 | CGEM | Trigilio Jeffrey | CFO | S - Sale+OE | $28.48 | -15.0K | 11.8K | -56% | -$427.2K |
| M | 2021-09-08 | 2021-09-03+ | CGEM | BioImpact Capital LLC | 10% | S - Sale | $29.20 | -48.6K | 7.69M | -0.6% | -$1.42M |
| MI | 2021-09-08 | 2021-09-03+ | CGEM | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.20 | -48.6K | 7.70M | -0.6% | -$1.42M |
| M | 2021-09-08 | 2021-09-03+ | CGEM | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.20 | -6,724 | 250.1K | -3% | -$196.4K |
| 2021-09-08 | 2021-09-07 | CGEM | Zawel Leigh | See Remarks | S - Sale | $28.95 | -28.1K | 65.4K | -30% | -$814.0K | |
| M | 2021-09-02 | 2021-08-31+ | CGEM | UBS Oncology Impact Fund L.P. | 10% | S - Sale | $29.50 | -24.3K | 7.74M | -0.3% | -$717.2K |
| MI | 2021-09-02 | 2021-08-31+ | CGEM | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.50 | -24.3K | 7.74M | -0.3% | -$717.2K |
| M | 2021-09-02 | 2021-08-31+ | CGEM | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.50 | -3,360 | 259.0K | -1% | -$99.1K |
| M | 2021-08-31 | 2021-08-27+ | CGEM | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.24 | -6,131 | 260.2K | -2% | -$179.3K |
| MI | 2021-08-31 | 2021-08-27+ | CGEM | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.24 | -44.4K | 7.76M | -0.6% | -$1.30M |
| M | 2021-08-31 | 2021-08-27+ | CGEM | Oncology Impact Fund (Cayman) Management L.P. | 10% | S - Sale | $29.24 | -44.4K | 7.76M | -0.6% | -$1.30M |
| D | 2021-08-26 | 2021-08-10 | CGEM | Baeuerle Patrick | See Remarks | S - Sale+OE | $27.00 | -11.0K | 0 | -100% | -$297.0K |
| D | 2021-08-26 | 2021-08-10 | CGEM | Baeuerle Patrick | See Remarks | M - OptEx | $4.30 | +11.0K | 11.0K | New | +$47.3K |
| DA | 2021-08-26 | 2021-08-18 | CGEM | Michaelson Jennifer | See Remarks | M - OptEx | $4.30 | +4,000 | 26.9K | +17% | +$17.2K |
| DMA | 2021-08-26 | 2021-08-18 | CGEM | Michaelson Jennifer | See Remarks | S - Sale+OE | $27.66 | -4,000 | 24.0K | -14% | -$110.6K |
| A | 2021-08-26 | 2021-08-23 | CGEM | Zawel Leigh | See Remarks | S - Sale | $29.00 | -28.1K | 93.5K | -23% | -$815.4K |
| MA | 2021-08-26 | 2021-08-09+ | CGEM | Zawel Leigh | See Remarks | S - Sale | $26.77 | -28.1K | 130.3K | -18% | -$752.9K |
| M | 2021-08-25 | 2021-08-23+ | CGEM | Oncology Impact Fund (Cayman) Management L.P. | 10% | S - Sale | $29.29 | -105.9K | 7.81M | -1% | -$3.10M |
| MI | 2021-08-25 | 2021-08-23+ | CGEM | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.29 | -106.0K | 7.86M | -1% | -$3.10M |
| M | 2021-08-25 | 2021-08-23+ | CGEM | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.29 | -14.6K | 266.5K | -5% | -$428.7K |
| 2021-08-24 | 2021-08-23 | CGEM | Zawel Leigh | See Remarks | S - Sale | $29.00 | -28.1K | 93.5K | -23% | -$815.4K | |
| DM | 2021-08-24 | 2021-08-18 | CGEM | Michaelson Jennifer | See Remarks | S - Sale+OE | $27.66 | -4,000 | 22.9K | -15% | -$110.6K |
| D | 2021-08-24 | 2021-08-18 | CGEM | Michaelson Jennifer | See Remarks | M - OptEx | $4.30 | +4,000 | 26.9K | +17% | +$17.2K |
| 2021-08-12 | 2021-08-11 | CGEM | MPM Oncology Impact Management GP LLC | 10% | S - Sale | $29.05 | -2,510 | 7.91M | -0.0% | -$72.9K | |
| I | 2021-08-12 | 2021-08-11 | CGEM | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.05 | -2,510 | 7.91M | -0.0% | -$72.9K |
| 2021-08-12 | 2021-08-11 | CGEM | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.05 | -347 | 280.9K | -0.1% | -$10.1K | |
| M | 2021-08-11 | 2021-08-09+ | CGEM | Zawel Leigh | See Remarks | S - Sale | $26.77 | -28.1K | 123.5K | -19% | -$752.9K |
Purchase Sale Sale after option exercise All abbreviations